Deep Bio, a local diagnostic company, said its prostate cancer analysis algorithm, DeepDx Prostate, will be integrated into Roche Diagnostics' Navify Digital Pathology platform.

Through this collaboration, Deep Bio aims to enhance its digital pathology capabilities and expand its comprehensive AI solutions as the integration of the company's algorithm into the Navify platform will enable Deep Bio to expand its global reach while providing new insights and data-driven solutions to improve diagnostic accuracy and treatment decisions.

DeepDx Prostate is a clinically validated AI tool designed to assist pathologists in the precise and efficient diagnosis of prostate cancer.

It aids in the identification of cancer types, grading severity, and measuring tumor and tissue size, enhancing diagnostic accuracy. The algorithm has undergone rigorous testing, having analyzed over 700,000 core needle biopsies in the U.S., and its reliability has been demonstrated through extensive clinical research published in multiple journals.

DeepDx Prostate also has received European CE certification and has been internationally recognized, winning the Edison Silver Award and the CES 2024 Innovation Award.

“We are thrilled to partner with Roche Diagnostics, a global leader in the diagnostic field, and this collaboration will enhance the accessibility and influence of our AI solutions,” Deep Bio CEO Kim Sun-woo said. “By integrating DeepDx Prostate into the Navify, pathologists worldwide will be able to strengthen their decision-making process in cancer diagnosis and ultimately improve the quality of patient care.”